Enhanced notch activation is advantageous but not essential for T cell lymphomagenesis in Id1 transgenic mice

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Wang, Hong Cheng ^a   Peng, Vincent ^b   Zhao, Ying ^a   Sun, Xiao Hong ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b Oklahoma School of Science and Mathematics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; DELTEX1 PROTEIN; IKAROS TRANSCRIPTION FACTOR; MYC PROTEIN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION 1; ZFPN1A1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GROWTH RATE; INTERMETHOD COMPARISON; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; NOTCH1 GENE; ONCOGENE; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T CELL LYMPHOMA; TUMOR GROWTH; ANIMAL; CHROMOSOME ABERRATION; CYTOLOGY; DIMERIZATION; FLOW CYTOMETRY; GENETICS; HUMAN; LYMPHOMA; METABOLISM; METHODOLOGY; PATHOLOGY; POINT MUTATION; T LYMPHOCYTE; THYMUS; TRANSGENE; TRANSGENIC MOUSE;

MUS MUSCULUS;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHROMOSOME ABERRATIONS; DIMERIZATION; FLOW CYTOMETRY; HUMANS; IKAROS TRANSCRIPTION FACTOR; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LYMPHOMA; MICE; MICE, TRANSGENIC; POINT MUTATION; RECEPTORS, NOTCH; T-LYMPHOCYTES; THYMUS GLAND; TRANSGENES;

EID: 84863242877     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032944     Document Type: Article

References (50)

1. Armstrong SA, Look AT, (2005) Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol 23: 6306-6315.
2. O'Neil J, Look AT, (2007) Mechanisms of transcription factor deregulation in lymphoid cell transformation. Oncogene 26: 6838-6849.
3. Baer R, (1993) TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin Cancer Biol 4: 341-347.
4. Wadman IA, Osada H, Grutz GG, Agulnick AD, Westphal H, et al. (1997) The LIM-only protein Lmo2 is a bridging molecule assembling an erythroid, DNA-binding complex which includes the TAL1, E47, GATA-1 and Ldb1/NLI proteins. EMBO J 16: 3145-3157.
5. Hsu HL, Wadman I, Tsan JT, Baer R, (1994) Positive and negative transcriptional control by the TAL1 helix-loop-helix protein. Proc Natl Acad Sci USA 91: 5947-5951.
6. Park ST, Sun XH, (1998) The Tal1 oncoprotein inhibits E47-mediated transcription. Mechanism of inhibition. J Biol Chem 273: 7030-7037.
7. O'Neil J, Ventura JJ, Cusson N, Kelliher MA, (2003) NF-{kappa}B activation in premalignant mouse tal-1/scl thymocytes and tumors. Blood.
8. O'Neil J, Shank J, Cusson N, Murre C, Kelliher M, (2004) TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell 5: 587-596.
9. Aplan PD, Jones CA, Chervinsky DS, Zhao X, Ellsworth M, et al. (1997) An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J 16: 2408-2419.
10. Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, et al. (1997) E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol 17: 4782-4791.
11. Yan W, Young AZ, Soares VC, Kelley R, Benezra R, et al. (1997) High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol Cell Biol 17: 7317-7327.
12. Kim D, Peng XC, Sun XH, (1999) Massive apoptosis of thymocytes in T-cell-deficient Id1 transgenic mice. Mol Cell Biol 19: 8240-8253.
13. Yang Y, Liou HC, Sun XH, (2006) Id1 potentiates NF-kappaB activation upon T cell receptor signaling. J Biol Chem 281: 34989-34996.
14. Morrow MA, Mayer EW, Perez CA, Adlam M, Siu G, (1999) Overexpression of the helix-loop-helix protein Id2 blocks T cell development at multiple stages. Mol Immunol 36: 491-503.
15. Dudley DD, Wang HC, Sun XH, (2009) Hes1 potentiates T cell lymphomagenesis by up-regulating a subset of notch target genes. PLoS One 4: e6678.
16. Pear WS, Aster JC, Scott ML, Hasserjian RP, Soffer B, et al. (1996) Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med 183: 2283-2291.
17. Fowlkes BJ, Robey EA, (2002) A reassessment of the effect of activated Notch1 on CD4 and CD8 T cell development. J Immunol 169: 1817-1821.
18. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, et al. (1991) TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 66: 649-661.
19. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, et al. (2004) Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271.
20. Grabher C, von Boehmer H, Look AT, (2006) Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 6: 347-359.
21. Aster JC, Blacklow SC, Pear WS, (2011) Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol 223: 262-273.
22. Dumortier A, Jeannet R, Kirstetter P, Kleinmann E, Sellars M, et al. (2006) Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol 26: 209-220.
23. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, et al. (2006) Activating Notch1 mutations in mouse models of T-ALL. Blood 107: 781-785.
24. Reschly EJ, Spaulding C, Vilimas T, Graham WV, Brumbaugh RL, et al. (2006) Notch1 promotes survival of E2A-deficient T cell lymphomas through pre-T cell receptor-dependent and-independent mechanisms. Blood 107: 4115-4121.
25. Chiang MY, Xu L, Shestova O, Histen G, L'heureux S, et al. (2008) Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest 118: 3181-3194.
26. Jeannet R, Mastio J, Macias-Garcia A, Oravecz A, Ashworth T, et al. (2010) Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood 116: 5443-5454.
27. Ashworth TD, Pear WS, Chiang MY, Blacklow SC, Mastio J, et al. (2010) Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood 116: 5455-5464.
28. Gomez-del Arco P, Kashiwagi M, Jackson AF, Naito T, Zhang J, et al. (2010) Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis. Immunity 33: 685-698.
29. Lewis HD, Leveridge M, Strack PR, Haldon CD, O'Neil J, et al. (2007) Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol 14: 209-219.
30. Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, et al. (2009) Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 69: 3060-3068.
31. Tatarek J, Cullion K, Ashworth T, Gerstein R, Aster JC, et al. (2011) Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood 118: 1579-1590.
32. Ferrando AA, (2009) The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program pp. 353-361.
33. Kox C, Zimmermann M, Stanulla M, Leible S, Schrappe M, et al. (2010) The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 24: 2005-2013.
34. Clappier E, Collette S, Grardel N, Girard S, Suarez L, et al. (2010) NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 24: 2023-2031.
35. Zuurbier L, Homminga I, Calvert V, te Winkel ML, Buijs-Gladdines JG, et al. (2010) NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 24: 2014-2022.
36. Larson GA, Chen Q, Kugel DS, Ge Y, LaFiura K, et al. (2009) The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 23: 1417-1425.
37. Yashiro-Ohtani Y, He Y, Ohtani T, Jones ME, Shestova O, et al. (2009) Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A. Genes Dev 23: 1665-1676.
38. Lin YW, Nichols RA, Letterio JJ, Aplan PD, (2006) Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood 107: 2540-2543.
39. O'Neil J, Calvo J, McKenna K, Krishnamoorthy V, Aster JC, et al. (2006) Activating Notch1 mutations in mouse models of T-ALL. Blood 107: 781-785.
40. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, et al. (2006) c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev 20: 2096-2109.
41. Tiyanont K, Wales TE, Aste-Amezaga M, Aster JC, Engen JR, et al. (2011) Evidence for increased exposure of the Notch1 metalloprotease cleavage site upon conversion to an activated conformation. Structure 19: 546-554.
42. Wang HC, Perry SS, Sun XH, (2009) Id1 attenuates Notch signaling and impairs T-cell commitment by elevating Deltex1 expression. Mol Cell Biol 29: 4640-4652.
43. Kim D, Xu M, Nie L, Peng XC, Jimi E, et al. (2002) Helix-loop-helix proteins regulate pre-TCR and TCR signaling through modulation of Rel/NF-kappaB activities. Immunity 16: 9-21.
44. Malecki MJ, Sanchez-Irizarry C, Mitchell JL, Histen G, Xu ML, et al. (2006) Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol Cell Biol 26: 4642-4651.
45. Tremblay M, Tremblay CS, Herblot S, Aplan PD, Hebert J, et al. (2010) Modeling T-cell acute lymphoblastic leukemia induced by the SCL and LMO1 oncogenes. Genes Dev 24: 1093-1105.
46. Qi Z, Sun XH, (2004) Hyperresponse to T-cell receptor signaling and apoptosis of Id1 transgenic thymocytes. Mol Cell Biol 24: 7313-7323.
47. Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, et al. (2001) Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 1: 4.
48. Murtaugh LC, Stanger BZ, Kwan KM, Melton DA, (2003) Notch signaling controls multiple steps of pancreatic differentiation. Proc Natl Acad Sci U S A 100: 14920-14925.
49. Deng CP, Zhang P, Haper JW, Elledge SJ, Leder P, (1995) Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
50. Bookout AL, Mangelsdorf DJ, (2003) Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl Recept Signal 1: e012.